Bupropion for the treatment of apathy in Huntington's disease: A multicenter, randomised, double-blind, placebo-controlled, prospective crossover trial.
OBJECTIVE:To evaluate the efficacy and safety of bupropion in the treatment of apathy in Huntington's disease (HD). METHODS:In this phase 2b multicentre, double-blind, placebo-controlled crossover trial, individuals with HD and clinical signs of apathy according to the Structured Clinical Inter...
Main Authors: | Harald Gelderblom, Torsten Wüstenberg, Tim McLean, Lisanne Mütze, Wilhelm Fischer, Carsten Saft, Rainer Hoffmann, Sigurd Süssmuth, Peter Schlattmann, Erik van Duijn, Bernhard Landwehrmeyer, Josef Priller |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5360242?pdf=render |
Similar Items
-
Prodromal Huntington disease as a model for functional compensation of early neurodegeneration.
by: Kathrin Malejko, et al.
Published: (2014-01-01) -
Apathy and atrophy of subcortical brain structures in Huntington's disease: A two-year follow-up study
by: Verena Baake, et al.
Published: (2018-01-01) -
White matter cortico-striatal tracts predict apathy subtypes in Huntington's disease
by: Audrey E. De Paepe, et al.
Published: (2019-01-01) -
Error processing in Huntington's disease.
by: Christian Beste, et al.
Published: (2006-01-01) -
The Role of the Immune System in Huntington’s Disease
by: Gisa Ellrichmann, et al.
Published: (2013-01-01)